Cumberland Pharmaceuticals (NASDAQ:CPIX) Stock Price Passes Above 200 Day Moving Average - Here's What Happened

Key Points

• Cumberland Pharmaceuticals shares crossed above their 200-day moving average (200‑day MA $3.40), trading as high as $4.25 and last at $4.06 on ~1.75M shares — about a 4.1% intraday gain.
• Analyst sentiment is mixed: Weiss Ratings reiterated a sell, Wall Street Zen upgraded to a buy, but MarketBeat shows a consensus rating of "Sell".
• Institutional investors have recently added positions (e.g., Perceptive Advisors, Marshall Wace, Dimensional), while the company remains a small-cap (~$60.7M) with a negative P/E (-21.37), indicating it is currently unprofitable.

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.40 and traded as high as $4.25. Cumberland Pharmaceuticals shares last traded at $4.06, with a volume of 1,750,980 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on CPIX shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Cumberland Pharmaceuticals in a research note on Friday, March 27th. Wall Street Zen raised Cumberland Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, March 14th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cumberland Pharmaceuticals presently has a consensus rating of "Sell".

Cumberland Pharmaceuticals Stock Up 4.1%

The company has a 50 day simple moving average of $3.43 and a two-hundred day simple moving average of $3.40. The company has a quick ratio of 0.84, a current ratio of 1.01 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $60.74 million, a P/E ratio of -21.37 and a beta of -0.33.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC bought a new position in shares of Cumberland Pharmaceuticals during the fourth quarter valued at approximately $1,358,000. Dimensional Fund Advisors LP grew its stake in shares of Cumberland Pharmaceuticals by 11.1% during the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company's stock valued at $876,000 after buying an additional 27,980 shares during the last quarter. Bridgeway Capital Management LLC grew its stake in shares of Cumberland Pharmaceuticals by 2.3% during the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company's stock valued at $631,000 after buying an additional 4,200 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Cumberland Pharmaceuticals by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company's stock valued at $427,000 after buying an additional 5,653 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Cumberland Pharmaceuticals during the fourth quarter valued at approximately $192,000. Institutional investors own 15.51% of the company's stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc NASDAQ: CPIX is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland's strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company's flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.